Huateng Pharma Highlights the Expanding Role of N-Benzylhydroxylamine Hydrochloride in Drug Discovery
Changsha, China – July 17, 2025 — Hunan Huateng Pharmaceutical Co., Ltd., a global supplier of pharmaceutical intermediates and PEG derivatives, is drawing attention to the growing scientific interest in N-Benzylhydroxylamine Hydrochloride (CAS 29601-98-7). With its distinctive nitrogen–oxygen (N–O) functional group, the compound is increasingly recognized for its broad applicability in modern medicinal chemistry and therapeutic research.
A Key Intermediate in HDAC Inhibitor Synthesis
N-Benzylhydroxylamine Hydrochloride has long served as a building block in the synthesis of hydroxamic acid-based compounds. Notably, it plays a role in the preparation of histone deacetylase (HDAC) inhibitors, such as Vorinostat (SAHA), which are used in oncology to modulate gene expression and promote cancer cell apoptosis.
Emerging Interest Beyond Oncology
Recent studies have begun to explore the compound’s potential beyond its synthetic utility:
Chelation Therapy: Its hydroxylamine group allows for the formation of stable complexes with transition metals, positioning it as a possible metal chelator in treatments for iron overload disorders, such as β-thalassemia.
Oxidative Stress Modulation: By scavenging reactive oxygen species (ROS), the compound may offer antioxidant effects relevant to neurodegenerative and cardiovascular diseases.
Antimicrobial and Antiviral Research: Its ability to interfere with metal-dependent enzymatic systems suggests potential in limiting bacterial proliferation and disrupting viral replication cycles.
Neurological Targets: Structural similarities with known monoamine oxidase (MAO) inhibitors and interaction potential with nitric oxide synthase (NOS) open avenues for investigation in neurological and inflammatory conditions.
Supporting Research Through Reliable Supply
As part of its commitment to advancing pharmaceutical science, Huateng Pharma manufactures N-Benzylhydroxylamine Hydrochloride under strict quality control standards, making it available to research institutions and pharmaceutical developers worldwide.
“We’ve observed a steady rise in demand for this compound, not only as a synthesis intermediate but also as a candidate for broader biomedical research,” said Jack Deng, CEO of Huateng Pharma. “We aim to support this momentum by ensuring consistent, high-quality supply for both research and commercial needs.”
About Huateng Pharma
Hunan Huateng Pharmaceutical Co., Ltd. is a global provider of PEG derivatives and pharmaceutical intermediates, serving clients from laboratory-scale development to full-scale production. The company’s portfolio supports innovation in biopharmaceuticals and small molecule drug development across a wide range of therapeutic areas.
For more information, visit:
Company Website: https://us.huatengsci.com/
Contact: sales@huatengusa.com